Brendan Walkden is a Principal based in the London office. Working for the majority of his career in major pharmaceutical companies Brendan has extensive experience of providing strategic business insight to support key marketing and investment decisions. Through this time Brendan has supported brands from early pre-launch through to patent expiry to maximise commercial potential.
Brendan obtained his PhD in membrane peptidase biochemistry from Leeds University UK. His research focused on the production of endothelin using animal cell models and using monoclonal antibodies to isolate key elements of the synthesis pathway.
Prior to joining Deallus in the London office, Brendan worked for 12 years in the business insights groups for several major pharmaceutical and biotech companies, most recently completing an assignment in the global analytics group for AstraZeneca working on the in-line and early emerging assets in the anti-infective franchise with particular focus on forecasting future product sales to support development investment decisions for early stage antibiotic development.
Prior to this he supported major market launches for Lundbeck and Amgen working in the fields of mental health and osteoporosis helping to develop brand strategy for the UK market. In addition Brendan has worked across a wide range of therapy areas including HIV, anti-fungals, pain and diabetes for Merck, managing market analysis, forecasting and primary market research projects supporting brands at all stages of the product lifecycle including market entry strategy, mature and growth brands and market exit programs for products approaching loss of patent protection to maximise sales revenues.